+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Anaplastic Astrocytoma Pipeline Analysis and Outlook, 2019

  • ID: 4772458
  • Report
  • 86 pages
  • VPA Research
until Dec 31st 2019
1 of 3


  • AbbVie Inc
  • Advantagene Inc
  • Astellas Pharma Inc
  • CDG Therapeutics Inc
  • Everfront Biotech Inc
  • Novartis Pharmaceuticals
  • MORE
Anaplastic Astrocytoma pipeline

Anaplastic Astrocytoma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Anaplastic Astrocytoma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Anaplastic Astrocytoma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Anaplastic Astrocytoma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Anaplastic Astrocytoma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Anaplastic Astrocytoma pipeline Profiled in detail

Key players actively participating in Anaplastic Astrocytoma pipeline are profiled along with their R&D progress in Anaplastic Astrocytoma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Anaplastic Astrocytoma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Anaplastic Astrocytoma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Anaplastic Astrocytoma pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Anaplastic Astrocytoma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Anaplastic Astrocytoma pipeline study
  • All recent news and developments related to Anaplastic Astrocytoma drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • AbbVie Inc
  • Advantagene Inc
  • Astellas Pharma Inc
  • CDG Therapeutics Inc
  • Everfront Biotech Inc
  • Novartis Pharmaceuticals
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Anaplastic Astrocytoma Disease Overview

3. Anaplastic Astrocytoma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Anaplastic Astrocytoma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Anaplastic Astrocytoma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Anaplastic Astrocytoma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Anaplastic Astrocytoma Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • AbbVie Inc
  • Aduro BioTech Inc
  • Advantagene Inc
  • AngioChem Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • CDG Therapeutics Inc
  • Curis Inc
  • Deciphera Pharmaceuticals LLC
  • Everfront Biotech Inc
  • Ipsen SA
  • Millennium Pharmaceuticals Inc
  • Novartis Pharmaceuticals
  • Orbus Therapeutics Inc
  • TheraBiologics Inc
  • Tocagen Inc
  • Tragara Pharmaceuticals Inc
  • Vanquish Oncology Inc
Note: Product cover images may vary from those shown